Business · 20/08/2026Updated: 10/17/2026 · 1 min read
FDA Renews Cardiovascular and Renal Drugs Advisory Committee for 2 Years
Summary
The Food and Drug Administration (FDA) is renewing the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on August 27, 2028. The Commissioner of Food and Drugs has made this decision in the public interest.
Original source language: Federal Register — Health and Human ServicesOpen original release →